Publications by authors named "P E Hamlin"
Purpose: We conducted a phase I/II study evaluating nivolumab plus doxorubicin, vinblastine, dacarbazine (N-AVD) as frontline therapy for treatment-naïve older adults (OA) with classical Hodgkin lymphoma (cHL; ClinicalTrials.gov identifier: NCT03033914).
Methods: Patients age ≥60 years with newly diagnosed, any stage, cHL were treated with six cycles of AVD at standard doses plus nivolumab 240 mg intravenously once every 2 weeks (on days 1 and 15) of each cycle.
SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review.
Clin Lymphoma Myeloma Leuk
November 2024
Article Synopsis
- Older adults with diffuse large B-cell lymphoma (DLBCL) face unique challenges and poorer outcomes, highlighting the need for tailored care strategies.
- Geriatric assessment (GA) tools, like simplified GA (sGA), help categorize patients into fit, unfit, and frail groups to guide treatment decisions, including dose adjustments for chemotherapy.
- New treatment options, including CAR-T cell therapy and bispecific antibodies, are evolving to better serve older adults, particularly those who are unable to tolerate traditional therapies or who experience relapse after initial treatment.
Article Synopsis
- The combination of rituximab and lenalidomide (R-len) is an effective treatment for relapsed/refractory indolent non-Hodgkin lymphoma (iNHL), specifically for follicular lymphoma (FL) and marginal zone lymphoma (MZL), with a significant overall response rate of 82%.
- In a study involving 84 patients, the median age at treatment initiation was 65, with a median progression-free survival of 22 months and a 2-year overall survival rate of 83%.
- Common adverse effects included hematologic toxicity, fatigue, and gastrointestinal issues, but overall safety aligned with previous clinical trials, suggesting R-len’s use in real-life settings is consistent with